Show simple item record

dc.contributor.authorSotirios, Grigoriou
dc.contributor.authorMartinez-Martin, Pablo 
dc.contributor.authorRay, Chaudhuri K
dc.contributor.authorKatarina, Rukavina
dc.contributor.authorValentina, Leta
dc.contributor.authorDenise, Hausbrand
dc.contributor.authorBjörn, Falkenburger
dc.contributor.authorPer, Odin
dc.contributor.authorHeinz, Reichmann
dc.identifier.citationBrain Behav. 2021 Oct;11(10):e2336.es_ES
dc.description.abstractBackground: Non-motor symptoms (NMS) are integral to Parkinson's Disease (PD) and management remains a challenge. Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties. Objective: To investigate the efficacy of safinamide on NMS and its burden in PD patients with motor fluctuations after 6 months of treatment. Methods: This observational, multicenter, open-label, pilot study assessed a wide range of NMS using the following rating scales, NMSS (non-motor symptom scale), KPPS (King's PD pain scale), HADS (hospital anxiety and depression scale), PDQ-8 (Parkinson's disease quality of life questionnaire), and PDSS-2 (Parkinson's disease sleep scale), EuroQol-5D 3 level version (EQ-5D-3L), CGI-I (clinical global impression of improvement), and PGI-C (patient global impression of change). Motor examination using UPDRS part III (Unified Parkinson's disease rating scale, motor examination), UPDRS IV (complications of therapy) and Hoehn and Yahr staging were also obtained. Results: 27 patients were included in the analysis and were evaluated at baseline and ≥ 6 months after safinamide treatment. 26 patients had a daily maintenance dose of 100 mg and 1 patient a daily dose of 50 mg. Significant improvements in UPDRS IV, KPPS item 5 (region-specific "off" dystonia), KPPS domain 3 (items 4-6, fluctuation related pain) and KPPS total score were observed after treatment with safinamide, while maintaining stable dopaminergic medication. No statistically significant differences were found in NMSS, HADS, PDSS-2, EQ-5D-3L, and PDQ-8 after treatment. Conclusions: Our results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients.es_ES
dc.description.sponsorshipThe study was funded by Zambon SpA with an unconditional research grant. In addition, the study was funded by MultiPark, the strategic research area for neuroscience at Lund University; the Swedish Parkinson Foundation; the Swedish Parkinson Academy and the Faculty of Medicine at Lund University.I was not given any grant numbers or any other details. The funds were used to finance the study personell and the logistic needs of the study.es_ES
dc.publisherWiley es_ES
dc.subjectMAO-B inhibitores_ES
dc.subjectParkinson's diseasees_ES
dc.subjectNon-motor symptomses_ES
dc.titleEffects of safinamide on pain in patients with fluctuating Parkinson's diseasees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderSwedish Parkinson Foundationes_ES
dc.contributor.funderSwedish Parkinson Academyes_ES
dc.contributor.funderLund University (Suecia)es_ES
dc.identifier.journalBrain and Behaviores_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional